大流行后时代多发性骨髓瘤合并COVID-19患者的管理:欧洲骨髓瘤网络(EMN)共识文件
欧洲骨髓瘤网络发布专家共识,指导大流行后时代多发性骨髓瘤(MM)合并COVID-19患者的管理。共识推荐使用变异株特异性加强疫苗,每6-12个月加强接种一次;口服抗病毒药(奈玛特韦/利托那韦、莫诺拉韦)和瑞德西韦应在新冠检测阳性时或症状出现后5天内给药;替沙格韦单抗/西加韦单抗暴露前预防因对新优势变异株无效不再推荐。
要点
- MM患者突破性感染和重症COVID-19(包括住院和死亡)风险增高。
- 推荐接种变异株特异性加强疫苗,末次接种或确诊感染后每6-12个月加强一次。
- 口服抗病毒药和瑞德西韦应在检测阳性时或症状出现后5天内给药。
核心结论
- 大流行后时代MM患者仍面临突破性感染和重症COVID-19高风险,EMN专家共识为患者管理提供指导。
研究设计与样本
- 欧洲骨髓瘤网络(EMN)制定的专家共识文件。
主要发现
- MM患者突破性感染和重症COVID-19结局(包括住院和死亡)风险增高。
- 加强针对抗CD38单克隆抗体对体液免疫应答的负面影响似乎有克服作用,但抗BCMA治疗仍为体液免疫应答的不良预测因素。
- 接种后免疫应答评估可识别可能需要额外加强针、预防性治疗和预防措施的特别脆弱患者亚群。
- 替沙格韦单抗/西加韦单抗暴露前预防对新优势变异株无效。
- 口服抗病毒药(奈玛特韦/利托那韦和莫诺拉韦)和瑞德西韦对Omicron亚变异株BA.2.12.1、BA.4、BA.5、BQ.1.1和/或XBB.1.5有效。
关键数值与推荐
- 加强接种应在末次疫苗注射或确诊COVID-19感染(混合免疫)后每6-12个月给予。
- 口服抗病毒药和瑞德西韦应在MM患者COVID-19检测阳性时或症状出现后5天内给药。
- 替沙格韦单抗/西加韦单抗暴露前预防不再推荐。
- SARS-CoV-2暴发期间的预防措施(包括戴口罩和避免拥挤场所)对MM患者似乎宜继续。
临床怎么用
- MM患者应接种变异株特异性加强疫苗,如针对祖先武汉株和Omicron BA.4/5株的二价疫苗。
- MM患者COVID-19检测阳性时或症状出现后5天内应给予口服抗病毒药或瑞德西韦。
- 不推荐使用替沙格韦单抗/西加韦单抗进行暴露前预防。
- SARS-CoV-2暴发期间MM患者似乎宜继续戴口罩和避免拥挤场所。
- 可评估接种后免疫应答以识别需要额外加强针、预防性治疗和预防措施的特别脆弱患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death. The European Myeloma Network has provided an expert consensus to guide patient management in this era. Vaccination with variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4/5 strains, is essential as novel strains emerge and become dominant in the community. Boosters should be administered every 6-12 months after the last vaccine shot or documented COVID-19 infection (hybrid immunity). Booster shots seem to overcome the negative effect of anti-CD38 monoclonal antibodies on humoral responses; however, anti-BCMA treatment remains an adverse predictive factor for humoral immune response. Evaluation of the immune response after vaccination may identify a particularly vulnerable subset of patients who may need additional boosters, prophylactic therapies and prevention measures. Pre-exposure prophylaxis with tixagevimab/cilgavimab is not effective against the new dominant variants and thus is no longer recommended. Oral antivirals (nirmatrelvir/ritonavir and molnupiravir) and remdesivir are effective against Omicron subvariants BA.2.12.1, BA.4, BA.5, BQ.1.1 and/or XBB.1.5 and should be administered in MM patients at the time of a positive COVID-19 test or within 5 days post symptoms onset. Convalescent plasma seems to have low value in the post-pandemic era. Prevention measures during SARS-CoV-2 outbreaks, including mask wearing and avoiding crowded places, seem prudent to continue for MM patients.
引用
- Terpos E, Musto P, Engelhardt M, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023. PMID: 37142661. doi:10.1038/s41375-023-01920-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。